CTA 382
Alternative Names: CTA-382Latest Information Update: 23 Jan 2025
Price :
$50 *
At a glance
- Originator Certa Therapeutics
- Class Small molecules; Urologics
- Mechanism of Action GPR68 protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic nephropathies; Kidney disorders
Most Recent Events
- 19 Dec 2024 Preclinical trials in Diabetic nephropathies in Australia (unspecified route) prior to December 2024 (Certa Therapeutics pipeline, January 2025)
- 19 Dec 2024 Preclinical trials in Kidney disorders in Australia (unspecified route), prior to December 2024 (Certa Therapeutics pipeline, January 2025)